GlaxoSmithKline plc (LON:GSK) Given a GBX 1,600 Price Target at Morgan Stanley

Morgan Stanley set a GBX 1,600 ($21.57) price target on GlaxoSmithKline plc (LON:GSK) in a report published on Friday, September 8th. The firm currently has a sell rating on the stock.

Several other equities research analysts have also commented on the stock. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.62) target price on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research report on Wednesday, July 26th. Barclays PLC restated an equal weight rating and set a GBX 1,550 ($20.90) target price on shares of GlaxoSmithKline plc in a research report on Monday, July 3rd. Jefferies Group LLC restated a buy rating and set a GBX 1,900 ($25.62) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Berenberg Bank upgraded shares of GlaxoSmithKline plc from a hold rating to a buy rating and boosted their target price for the stock from GBX 1,850 ($24.94) to GBX 1,885 ($25.41) in a research report on Friday, May 26th. Finally, Deutsche Bank AG restated a hold rating and set a GBX 1,720 ($23.19) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 25th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of GBX 1,698.52 ($22.90).

GlaxoSmithKline plc (LON GSK) traded up 0.41% during mid-day trading on Friday, hitting GBX 1474.00. 5,726,851 shares of the stock were exchanged. The stock’s 50 day moving average is GBX 1,503.38 and its 200 day moving average is GBX 1,606.97. GlaxoSmithKline plc has a 52-week low of GBX 1,444.00 and a 52-week high of GBX 1,745.56. The stock’s market cap is GBX 72.05 billion.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/09/25/glaxosmithkline-plc-gsk-pt-set-at-gbx-1600-by-morgan-stanley.html.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was purchased at an average price of GBX 1,599 ($21.56) per share, with a total value of

Several other equities research analysts have also commented on the stock. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.62) target price on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research report on Wednesday, July 26th. Barclays PLC restated an equal weight rating and set a GBX 1,550 ($20.90) target price on shares of GlaxoSmithKline plc in a research report on Monday, July 3rd. Jefferies Group LLC restated a buy rating and set a GBX 1,900 ($25.62) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Berenberg Bank upgraded shares of GlaxoSmithKline plc from a hold rating to a buy rating and boosted their target price for the stock from GBX 1,850 ($24.94) to GBX 1,885 ($25.41) in a research report on Friday, May 26th. Finally, Deutsche Bank AG restated a hold rating and set a GBX 1,720 ($23.19) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 25th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of GBX 1,698.52 ($22.90).

GlaxoSmithKline plc (LON GSK) traded up 0.41% during mid-day trading on Friday, hitting GBX 1474.00. 5,726,851 shares of the stock were exchanged. The stock’s 50 day moving average is GBX 1,503.38 and its 200 day moving average is GBX 1,606.97. GlaxoSmithKline plc has a 52-week low of GBX 1,444.00 and a 52-week high of GBX 1,745.56. The stock’s market cap is GBX 72.05 billion.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/09/25/glaxosmithkline-plc-gsk-pt-set-at-gbx-1600-by-morgan-stanley.html.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was purchased at an average price of GBX 1,599 ($21.56) per share, with a total value of £36,249.33 ($48,873.30). Also, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.81) per share, with a total value of £13,930.98 ($18,782.50). In the last three months, insiders have purchased 3,152 shares of company stock valued at $5,055,023.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply